Drug Profile
Iloperidone - Vanda Pharmaceuticals
Alternative Names: Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; ZomarilLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer MegaPharm Ltd; Novartis; PROBIOMED; University of Colorado at Denver; Vanda Pharmaceuticals
- Class Antipsychotics; Isoxazoles; Mood stabilisers; Piperidines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Schizophrenia
- Preregistration Bipolar disorders
- Phase II Post-traumatic stress disorders; Psychotic disorders
- No development reported Unspecified
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Schizophrenia in USA (Injection, Controlled release)
- 08 Nov 2023 Preregistration for Bipolar disorders (In the elderly, In adults) in USA (PO)
- 08 Nov 2023 FDA assigns PDUFA action date of 02/04/2024 for iloperidone (Fanapt®) for Bipolar disorder